Recently, we proposed a hypothesis regarding the suppressive effects of cancer cachexia on PD‐1/PD‐L1 inhibitors in patients with metastatic non‐small cell lung cancer (NSCLC).8 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.